Home | Privacy Policy | Terms of Use | Endnotes

Life ABC - Life After early Breast Cancer

Improving Your Chance
          of Staying Cancer Free

Home > Endnotes

Endnotes

1 National Cancer Institute. Probability of Breast Cancer in American Women. Accessed April 30, 2005. Available at: http://cis.nci.nih.gov/fact/5_6.htm

2 Avon Foundation. Breast Health Resource Guide. Accessed April 12, 2005. Available at: http://www.avoncompany.com/women/avoncrusade/bccguide.pdf.

3 American Cancer Society. Breast Cancer Facts & Figures 2003-2004. Accessed April 20, 2005. Available at: http://www.cancer.org/downloads/STT/CAFF2003BrFPWSecured.pdf.

4 General Breast Cancer Info: Breast Cancer Cases/Deaths Per Year (U.S. and World). Accessed April 12, 2005. Available at: http://imaginis.com/breasthealth/statistics.asp?mode=1.

5 Singletary S. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628.

6 Vadhat L, MD, director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, Weill Medical College of Cornell University. Provided April 27, 2005.

7 National Women's Health Information Center. Why would any woman pick mastectomy if the survival rate is the same? Accessed April 12, 2005. Available at: http://www.4woman.gov/faq/earlybc.htm.

8 National Cancer Institute. Surgery choices for women with early breast cancer. Accessed April 12, 2005. Available at: http://www.nci.nih.gov/cancertopics/breast-cancer-surgery-choices.

9 Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1466.

10 Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med. 1989;320:479-484.

11 Fisher B, Jeong J-H, Bryant J, et al. Treatment of lymph-node-negative, estrogen receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet. 2004;364:858-868.

12 Fisher B, Dignam J, Bryant J, DeCillis A, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Can Inst. 1996;88:1529-1542.

13 Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Can Inst. 2001;93:684-689.

14 Chia S, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004;22:1630-1637.

15 Olivotto, IA, Bajdik, CD, Plenderleith, IH, et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med. 1994;330:805-810.

16 Garrett TJ, Vahdat LT, Kinne DW. Systemic adjuvant therapy of breast cancer. J Surg Oncol.1997;64:167-172.

17 Mcguire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med. 1992;326:1756.

18 Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738-2746.

19 Goss PE, Ingle JN. Updated analysis of the NCIC CTG MA.17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol. 2004;23:87. Abstract 847.

20 Hortobagyi, GN, Kau, S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol. 2004;22(suppl14s). Abstract 585.

21 American Cancer Society. Accessed April 29, 2005. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Hormone_Therapy_5.asp?sitearea=.

22 Life After Breast Cancer: Special Analysis Of Women Having Completed Or Nearly Completed Adjuvant Therapy As To Their Outlook On Life. Roper Public Affairs and NOP World. 2005;1-30.

23 Gurmankin AD. Coping after breast cancer: how fear of recurrence impacts interpretation of and response to symptoms. Unpublished data.

24 Gurmankin AD, Baron J, Armstrong K. Intended message versus message received in hypothetical physician risk communications: exploring the gap. Risk Anal. 2004;24:1337-1347.

25 Gurmankin AD, Domchek S, Stopfer J, et al. Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Int Med. 2005;165:523-529.

26 Sutherland H, Thomas H, Lockwood G, Tritchler D, Till J. Cancer patients: their desire for information and participation in treatment decisions. J Roy Soc Med. 1989;82:260-263.

27 Brody H. Autonomy revisited: progress in medical ethics: discussion paper. J Roy Soc Med. 1985:78:380-387.

28 Thomasma DC. Autonomy in the doctor-patient relation. Theor Med. 1984:5:1-7.

29 Oken D. What to tell cancer patients: a study of medical attitudes. JAMA. 1961;175:1120-1128.

30 Novack DH, Plumer R, Smith RL, Ochitill H, Morrow GR, Bennett JM. Changes in healthcare professionals' attitudes toward telling the cancer patient. JAMA. 1979;241:897.

31 Deber R, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision-making? Arch Intl Med. 1996;156(13):1414-1420.

32 Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients' desire for autonomy; decision making and information-seeking preferences among medical patients. J Gen Intern Med. 1989;4:23-30.

33 Strull WM, Lo B, Charles G. Do patients want to participate in medical decision making? JAMA. 1984; 252:2990-2994.

34 Degner L, Kristjanson L, Bowman D, Sloan J, Carriers K, O'Neil J, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485-1492.

35 Cassileth BR. Information and participation preferences among cancer patients. Ann Intern Med. 1980;92:832-836.

36 Degner LF, Preferences for treatment control among adults with cancer. Res Nurs Health. 1988;11:367-374.

37 Beisecker AE. Patient information-seeking behavior when communicating with doctors. Med Care. 1990;28:19-28.

38 Blanchard CG. Information and decision-making preferences of hospitalized adult cancer patients. Soc Sci Med. 1988;27:1139-1145.

39 Guadagnoli E., Ward P. Patient participation in decision-making. Soc Sci Med. 1998;47(3):329-339.

40 Deber Rb, Baumann AO. Clinical reasoning in medicine and nursing: decision making versus problem solving. Teach Learn Med. 1992;4:140-146.

41 Baumann AO, Deber RB. Decision Making and Problem Solving in Nursing: An Overview and Analysis of Relevant Literature. Toronto, Ontario: University of Toronto, Faculty of Nursing; 1989.

42 Gurmankin AD, Baron J, Hershey J. The role of physicians' recommendations in medical treatment decisions. Med Decis Making. 2002;22:262-271.

43 Siminoff L, Fetting J. Factors affecting treatment decisions for life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med. 1991;32:813-818.

44 Kalet A, Roberts J, Fletcher R. How do physicians talk with their patients about risk? J Gen Int Med. 1994;9:402-404.

45 Kreuter MW. Dealing with competing and conflicting risks in cancer communication. JNCI. 1999;25;27-35:32.

46 Fischhoff, B. Why (cancer) risk communication can be hard. JNCI. 1999;25:7-13.

47 Weinstein N. What does it mean to understand a risk? Evaluating risk comprehension. JNCI. 1999;25:15-20.

48 Weinstein ND. Unrealistic optimism about susceptibility to health problems: conclusions from a community-wide sample. J Behav Med. 1987;10:481-500.

49 Weinstein ND. Unrealistic optimism about future life events. J Pers Soc Psych. 1987;39(5)806-820.

50 Weinstein, ND. Unrealistic optimism about susceptibility to health problems. J Behav Med. 1982;5:441-460.

51 McCaul KD, O'Donnell SM. Na�ve beliefs about breast cancer risk. Women's Health: Research on Gender, Behavior and Policy. 1998;4:93-101.

52 Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res and Trea. 2003;77:285-293.

53 Aspinwall LG. Introduction of section: Persuasion for the purpose of cancer risk reduction: understanding responses to risk communications. JNCI. 1999;25:88-93.

54 Black WC, Nease RF, Tosteson A. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Nat Can Inst. 1995;87(10):720-731.

55 Ravdin PM, Siminoff IA, Harvey, JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515-521.

56 Kelly K, Leventhal H, Baran J, et al. Perceived risk and distress in individuals receiving counseling for BRCA1 and BRCA2 mutations. Poster session presented at the annual meeting of the Society of Behavioral Medicine; 1999 Mar; San Diego, CA.

57 Rimer BK, Glassman B. Is There a use for tailored print communications in cancer risk communication? JNCI. 1999;25:140-148.

58 Leventhal H, Kelly K, Leventhal EA. Population risk, actual risk, perceived risk, and cancer control: a discussion. JNCI. 1999;25:81-85.

59 McCrary S. Christensen R. Slang 'On Board': A moral analysis of medical jargon. Arch Fam Med. 1993; 2:101-105.

60 Taylor KM. "Telling bad news": healthcare professionals and the disclosure of undesirable information. Sociol Health Ill. 1988;10:109-132.

61 Klausner R. Foreword. JNCI. 1999;25:1.

62 Stewart M. Effective Physician-patient communication and health outcomes: a review. Can Med Assoc J. 1995;9.

63 Rothman A, Kiviniemi M. Treating People with information: an analysis and review of approaches to communicating health risk information. JNCI. 1999;25:44-51.

64 Lipkus I, Klein W, Rimer B. Communicating breast cancer risks to women using different formats. Can Epidem Biomarkers & Prev. 2001;10:895-898.